AstraZeneca’s COVID-19 antibody therapy meets main goal in late study

(Reuters) – AstraZeneca said on Friday its antibody therapy met the main goal of preventing COVID-19 infection in a late-stage study.

The company said the treatment reduced the risk of developing symptomatic COVID-19 by 77%.

(Reporting by Muvija M in Bengaluru; Editing by Sriraj Kalluvila)